IMA ImageneBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $800,000 | $0 |
| R&D expense | $11.27M | $6.67M | $5.96M | $3.27M | $15.16M | $5.65M | $4.04M | $3.76M |
| SG&A expense | $6.04M | $5.12M | $6.12M | $5.23M | $11.04M | $1.71M | $2.75M | $2.38M |
| Operating income | -$17.31M | -$11.78M | -$12.08M | -$8.50M | -$26.19M | -$7.36M | -$6.00M | -$6.14M |
| Pretax income | -$15.60M | -$10.16M | -$10.61M | -$7.18M | -$24.85M | -$7.58M | -$6.08M | -$4.80M |
| Income tax | $20,000 | $16,000 | $10,000 | -$276,000 | -$74,000 | $15,000 | $28,000 | $13,000 |
| Net income | -$15.62M | -$10.18M | -$10.62M | -$6.91M | -$24.78M | -$7.58M | -$6.08M | -$4.81M |
| EBITDA | -$17.31M | -$11.78M | -$12.08M | -$8.11M | -$26.36M | -$7.36M | -$5.99M | -$6.16M |
| EPS (basic) | -0.91 | -0.63 | -0.95 | — | -2.91 | -4.46 | -3.80 | — |
| EPS (diluted) | -0.91 | -0.63 | -0.95 | — | -2.91 | -4.46 | -3.80 | — |
| Weighted avg. shares (diluted) | 17.12M | 16.16M | 11.21M | — | 8.80M | 2.41M | 2.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $84.85M | $94.68M | $76.05M | $94.53M | $103.16M | $6.02M | $4.92M | $12.12M |
| Short-term investments | $41.74M | $41.48M | $41.16M | $40.82M | $39.42M | $37.35M | $77.29M | $0 |
| Current assets | $130.60M | $141.11M | $122.01M | $140.29M | $147.53M | $99.01M | $117.00M | $12.47M |
| PP&E, net | — | — | — | $0 | $1,000 | $419,000 | $506,000 | $8,000 |
| Total assets | $142.54M | $152.04M | $136.68M | $152.98M | $160.88M | $126.17M | $130.84M | $15.92M |
| Current liabilities | $8.07M | $6.57M | $6.63M | $11.23M | $11.14M | $7.32M | $8.79M | $17.21M |
| Short-term debt | — | — | — | $0 | $0 | — | — | $7.50M |
| Total liabilities | $14.40M | $9.97M | $13.36M | $19.84M | $21.05M | $10.26M | $12.59M | $17.45M |
| Shareholders' equity | $128.14M | $142.07M | $123.33M | $133.14M | $139.83M | -$180.35M | -$169.60M | -$160.56M |
| Shares outstanding | — | — | — | — | — | 48.26M | 48.26M | 48.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.52M | -$9.07M | -$14.80M | -$7.22M | -$26.64M | -$11.90M | -$7.23M | -$3.48M |
| Investing cash flow | -$385,000 | -$346,000 | -$440,000 | -$1.36M | -$37.33M | $0 | $0 | $103,000 |
| Financing cash flow | $82,000 | $28.05M | -$3.24M | $0 | $122.42M | $13.02M | $27,000 | $6.91M |
| Depreciation & amortization | $0 | $0 | $0 | $394,000 | -$168,000 | $2,000 | $2,000 | -$19,000 |
| Stock-based compensation | $1.67M | $911,000 | $876,000 | $51,000 | $15.28M | $0 | $57,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.